New Brunswick treatments

ROCHE: Evrysdi – Risdiplam


Effective May 24- , 2022 – According to Bulletin 1008, EVRYSDIⓇ (risdiplam) will be covered through the New Brunswick Drug Formulary. For the treatment of 5q spinal muscular atrophy (SMA), if the following criteria are met:
• Genetic documentation of 5q SMA homozygous gene deletion, or compound heterozygous
mutation; and
• Patient is not requiring permanent invasive ventilation; and
• Patient who is symptomatic with two or three copies of the SMN2 gene and is:
– 2 months to 7 months of age, or
– 8 months to 25 years of age and non-ambulatory.
Discontinuation Criteria:
• There is failure to demonstrate maintenance in motor milestone function as assessed using
age-appropriate scales since treatment initiation; or
• permanent invasive ventilation is required Clinical Notes: 1. An age-appropriate scale is defined as the Hammersmith Infant Neurological Examination (HINE) Section 2, Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), or Hammersmith Functional Motor Scale-Expanded (HFMSE). New Brunswick Drug Plans 5 May 2022 2. A baseline assessment using an age-appropriate scale must be completed prior to initiation of treatment. 3. Yearly assessments must be completed using an age-appropriate scale no more than 12 weeks prior to the renewal date. 4. Permanent invasive ventilation is defined as the use of tracheostomy and a ventilator due to progression of SMA that is not due to an identifiable and reversible cause.

BIOGEN: Nusinersen – Spinraza


Initiation Criteria
1. Pre-symptomatic patients with two or three copies of the SMN2 gene, OR

2. Had the disease for <6 months, two copies of SMN2, and symptom onset after the first week after birth and on, or before seven months of age; OR 3. Patients under the age of 18 with symptom onset > 6 months of age, and never achieved the ability to walk independently.†

Stopping Criteria
1. For those pre-symptomatic at initiation: no improvement on HINE-2, CHOP INTEND, or HFMSE, OR

2. For those symptomatic at initiation: no improvement in HINE-2, CHOP INTENT, or HFMSE, OR

3. Permanent invasive ventilation required

“Requests for patients who do not meet the above criteria may be considered on a case-by-case basis.”

NOVARTIS: Onasemnogene abeparvovec – Zolgensma




SPACES is a first-of-its-kind musical collaboration created for everyone with a disability by the SMA community. Each creative component of the program – song, music video and album art – was led by someone with SMA. It uses the universal language of music to elevate the many voices of this community and celebrate our individuality…

August is Spinal Muscular Atrophy (SMA) Awareness month!

August is Spinal Muscular Atrophy (SMA) Awareness month! Cure SMA Canada spreads awareness throughout Canada to bring hope to a future where SMA is a curable disease.   This year, the CN Tower and the Montreal Tower will be lit up in purple and orange, the Cure SMA Canada colours, on August 19 from 6:30pm…

Activist Sammy Cavallaro awarded Quebec National Assembly Medal of Honour

We are so so proud of the achievements of Sammy Cavallaro!  Congratulations on your award Sammy!  Thank you to the Cavallaro family for your dedication to improving life for people affected by SMA in Canada! You teach us all to make a change where one is needed.  Very deserving of the award, we are so…


103-7134 VEDDER RD.


TOLL FREE 855.824.1277

BC 604.824.1277

FAX 604.824.1363


Please email Susi Vander Wyk at head office